Trulicity
dulaglutide
Table of contents
Overview
Trulicity is a diabetes medicine used in adults with type 2 diabetes when the disease is not controlled well enough. It is used with exercise and diet suitable for controlling diabetes.
Trulicity can be used together with other diabetes medicines or it can be used on its own in patients who cannot take metformin.
Trulicity contains the active substance dulaglutide.
-
List item
Trulicity : EPAR - Medicine overview (PDF/114.3 KB)
First published: 19/12/2014
Last updated: 28/04/2021
EMA/557897/2019 -
-
List item
Trulicity : EPAR - Risk-management-plan summary (PDF/575.56 KB)
First published: 19/12/2014
Last updated: 01/02/2021
EMA/601943/2014
Authorisation details
Product details | |
---|---|
Name |
Trulicity
|
Agency product number |
EMEA/H/C/002825
|
Active substance |
dulaglutide
|
International non-proprietary name (INN) or common name |
dulaglutide
|
Therapeutic area (MeSH) |
Diabetes Mellitus, Type 2
|
Anatomical therapeutic chemical (ATC) code |
A10BJ05
|
Publication details | |
---|---|
Marketing-authorisation holder |
Eli Lilly Nederland B.V.
|
Revision |
16
|
Date of issue of marketing authorisation valid throughout the European Union |
21/11/2014
|
Contact address |
Papendorpseweg 83 |
Product information
17/06/2021 Trulicity - EMEA/H/C/002825 - PSUSA/00010311/202009
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Drugs used in diabetes
-
Blood glucose lowering drugs, excl. insulins
Therapeutic indication
Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.
Assessment history
News
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 202327/01/2023
-
20/09/2019
-
26/09/2014